and S levels and activated protein C resistance (APCR) ratio were normal. Prothrombin gene mutation screen and Janus Kinase 2 (JAK2) were negative. Homocysteine level was insignificantly elevated at 14.8 (normal 4-12). Paroxysmal nocturnal hemoglobinuria was ruled out with negative cell markers for CD55 and CD59. A 24-hour urine collection was negative for nephrotic syndrome.
Screening for APS revealed a negative VDRL screen, but a positive dilute activated partial thromboplastin time with a positive 1:1 mix, suggesting the presence of a lupus-like inhibitor. As a result, she was also investigated for a possible connective tissue disease (CTD). Her history was unrevealing for any symptoms of CTD. She had an elevated erythrocyte sedimentation rate (46) and C-reactive protein (13.8). Antinuclear antibody, extractable nuclear antigens, rheumatoid factor, anticitrullinated protein antibody (anti-CCP), antineutrophil cytoplasmic antibodies, complement levels, immunoglobulins, and protein electrophoresis were all normal. Screening for hepatitis B and C and HIV revealed a positive hepatitis C serology. However, she was negative for cryoglobulins.
Polyarteritis nodosa and other large-vessel vasculitides were ruled out as she did not fit diagnostic criteria and the CT angiogram showed no evidence of aneurysms or vessel wall thickening consistent with inflammation. Buerger's disease was ruled out as she had no evidence of acral involvement. Blood cultures and transesophageal echocardiography were negative for evidence of endocarditis.
With her positive nonspecific inhibitor, a presumptive diagnosis of APS was made. She was anticoagulated with dalteparin, transitioned to warfarin and was discharged home. Her followup visit 5 months later confirmed the presence of a lupus-like inhibitor.
APS is considered secondary if it occurs with other related autoimmune diseases such as systemic lupus erythematosus. Primary APS is diagnosed when the presence of other related diseases is excluded.
The Sapporo criteria 2 require one clinical criterion (vascular thrombosis or pregnancy mortality before 10 weeks) and one laboratory criterion (one of lupus anticoagulant, anticardiolipin antibody, or anti-ß 2 -glycoprotein antibody are positive twice at least 12 weeks apart) for diagnosis of APS. The 3 laboratory criteria are used because of the variability of APS cases, as not all patients present homogenously 3, 4 .
Our patient had an extremely rare form of thrombosis in the great vessels. To our knowledge, there are only 4 other case reports in the literature 3, 4, 5, 6 -none with the feature of complete aortic occlusion observed in this patient.
Thus, our patient fit the clinical criteria with extensive splenic, kidney, superior mesenteric artery, and aortic thrombi, and pregnancy loss at 10 
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